The novel CD19-targeting antibody-drug conjugate huB4-DGN462 shows improved anti-tumor activity compared to SAR3419 in CD19-positive lymphoma and leukemia models. - Hicks SW; Tarantelli C; Wilhem A; Gaudio E; Li M; Arribas AJ; Spriano F; Bordone R; Cascione L; Lai KC; Qiu Q; Taborelli M; et al. (Haematologica, 2019)